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A B S T R A C T
Solution chemical properties of two bidentate pyrazolyl thiosemicarbazones 2-((3-methyl-1-phenyl-1H-pyrazol-
4-yl)methylene)hydrazinecarbothioamide (Me-pyrTSC), 2-((1,3-diphenyl-1H-pyrazol-4-yl)methylene)hy-
drazinecarbothioamide (Ph-pyrTSC), stability of their Cu(II) and Ru(η6-p-cymene) complexes were characterized
in aqueous solution (with 30% DMSO) by the combined use of UV–visible spectrophotometry, 1H NMR spec-
troscopy and electrospray ionization mass spectrometry in addition to their solid phase isolation. The solid phase
structures of Me-pyrTSC∙H2O, [Ru(η6-p-cymene)(Me-pyrTSC)Cl]Cl and [Cu(Ph-pyrTSCH−1)2] were determined
by single crystal X-ray diffraction. High stability mononuclear Ru(η6-p-cymene) complexes with (N,S) co-
ordination mode are formed in the acidic pH range, and increasing the pH the predominating dinuclear [(Ru(η6-
p-cymene))2(L)2]2+ complex with μ2-bridging sulphur donor atoms is formed (where L− is the deprotonated
thiosemicarbazone). [CuL]+ and [CuL2] complexes show much higher stability compared to that of complexes of
the reference compound benzaldehyde thiosemicarbazone. [CuL2] complexes predominate at neutral pH. Me-
pyrTSC and Ph-pyrTSC exhibited moderate cytotoxicity against human colonic adenocarcinoma cell lines
(IC50= 33–76 μM), while their complexation with Ru(η6-p-cymene) (IC50= 11–24 μM) and especially Cu(II)
(IC50= 3–6 μM) resulted in higher cytotoxicity. Cu(II) complexes of the tested thiosemicarbazones were also
cytotoxic in three breast cancer and in a hepatocellular carcinoma cell line. No reactive oxygen species pro-
duction was detected and the relatively high catalase activity of SUM159 breast cancer cells was decreased upon
addition of the ligands and the complexes. In the latter cell line the tested compounds interfered with the
glutathione synthesis as they decreased the concentration of this cellular reductant.
1. Introduction
Thiosemicarbazones (TSCs) are versatile compounds and known for
their wide pharmacological activity including anticancer properties
[1,2]. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarba-
zone) is the best-known representative of this family and was ex-
tensively investigated in numerous clinical phase I and II trials in mono
or combination therapies [3,4]. Two new promising TSCs, namely N′-
(6,7-dihydroquinolin-8(5H)-ylidene)-4-(pyridin-2-yl)piperazine-1-car-
bothiohydrazide (COTI-2, an orally available third generation TSC) and
di-2-pyridylketone-4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC)
also entered human clinical studies in the last years [5,6]. These com-
pounds belong to the family of α-N-pyridyl TSCs, therefore are
considered as tridentate ligands with a typical (Npyridyl,N,S) coordina-
tion mode with strong affinity towards various metal ions including Fe
(II/III) and Cu(II) [7]. The anticancer properties of Triapine are con-
nected to the inhibition of the iron-containing ribonucleotide reductase
enzyme and the formation of redox-active iron complexes in the cells is
suggested to be a crucial step of the mechanism of action [8]. On the
other hand, other essential metal ions (especially copper) besides iron
have been associated with the mechanism of action of TSCs [9–11]. α-
N-pyridyl- and salicylaldehyde-type TSCs are able to form mono-ligand
Cu(II) complexes with high solution stability at physiological pH with
(Npyridyl,N,S−) and (O−,N,S−) coordination modes, respectively
[12–14]. Till now numerous Cu(II) complexes of TSCs were developed
for anticancer activity [15,16] and generation of reactive oxygen
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species (ROS) is often assumed to be the mode of action [17,18], al-
though it is not true in all cases [7,19]. In addition to Cu(II) other metal
ions such as Pd(II), Ga(III), half-sandwich organometallic ions
[15,20–23] can also form complexes with TSCs owing significant cy-
totoxicity via different mechanisms of action and multiple targets.
For understanding of the anticancer activity of TSCs and their metal
complexes and for investigation of structure-activity relationships the
knowledge on their solution speciation and the most probable solution
structures under physiological conditions is of primary importance. The
anticancer TSC compounds are often characterized only in solid phase
or in organic solvents, and information about their behaviour in aqu-
eous solution is still limited. Although solution speciation of numerous
Cu(II) and Fe(II)/(III) complexes of α-N-pyridyl- and salicylaldehyde-
type TSCs was determined in our previous works [12–14,24], no
available stability data are published for the complexes of bidentate
TSCs so far. In this work our aim was to reveal the differences of the
complex formation with Cu(II) ions between two bidentate pyrazolyl
TSCs Me-pyrTSC, Ph-pyrTSC (Chart 1) and tridentate TSCs, and to
characterize the complexation of these ligands with the half-sandwich
organometallic [Ru(η6-p-cymene)(H2O)3]2+. The bis-ligand Pd(II)
complexes of them were reported to be rather cytotoxic against MCF7
breast cancer cell lines (IC50= 0.57–1.24 μM) [25], but no cytotoxicity
data were published for their Cu(II) and Ru(η6-p-cymene) complexes.
Therefore, solution speciation, solid phase structures of Cu(II) and
Ru(η6-p-cymene) complexes of the selected bidentate pyrazolyl TSCs
were investigated by different methods such as UV–visible (UV–vis)
spectrophotometry, 1H, 13C NMR and electron paramagnetic resonance
(EPR) spectroscopy, electrospray ionization mass spectrometry (ESI-
MS) and X-ray crystallography. Additionally, anticancer activity via
cytotoxicity assays, ROS production, catalase activity and L-glutathione
(GSH) levels were also monitored.
2. Experimental
2.1. Chemicals
All solvents were of analytical grade and used without further
purification. All solvents used for the ligand synthesis were distilled
shortly prior to use. [Ru(η6-p-cymene)(μ-Cl)Cl]2, benzaldehyde thiose-
micarbazone (Bz-TSC), CuCl2, KCl, HCl, KOH, NaH2PO4, Na2HPO4, di-
methyl sulfoxide (DMSO), EDTA, 4-(2-hydroxyethyl)-1-piper-
azineethanesulfonic acid (HEPES), maltol, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT), N-acetyl-cysteine (NAC), 2,7-
dichlorodihydrofluorescein diacetate (DCFH-DA), 2,2′-dinitro-5,5′-di-
thiodibenzoic acid (DTNB) and 4,4-dimethyl-4-silapentane-1-sulfonic
acid (DSS) were purchased from Sigma-Aldrich in puriss quality. Milli-
Q water was used for sample preparation. CuCl2 stock solution was
made by the dissolution of anhydrous CuCl2 in water and its exact
concentration was determined by complexometry through the EDTA
complex. The exact concentration of aqueous stock solution of Ru(η6-p-
cymene) prepared by the dissolution of [Ru(η6-p-cymene)(μ-Cl)Cl]2 was
determined by pH-potentiometric titrations in the presence of 0.2M
chloride ions employing stability constants for [(Ru(η6-p-cymene))2(μ-
OH)i](4−i)+ (i=2 or 3) complexes [26]. The stock solution of Bz-TSC
and Ph-pyrSC was prepared on a weight-in-volume basis dissolved in
DMSO, while the purity of Me-pyrTSC and Ph-pyrTSC was checked by
1H NMR spectroscopy in DMSO‑d6 using maltol as internal standard.
2.2. Synthesis of Me-pyrTSC, Ph-pyrTSC and Ph-pyrSC
Compounds Me-pyrTSC, Ph-pyrTSC and Ph-pyrSC were prepared
according to the literature [27,28] with some modifications. The syn-
thetic route (Scheme S1) and characterization of the products are found
in the Supplementary Information. General procedure for the synthesis
of hydrazones (2a and 2b): phenylhydrazine (1.18mL, 12.0 mmol) and
a catalytic amount of acetic acid (AcOH, 0.1mL) were added to a so-
lution of acetone (1a, 0.74mL, 10.0mmol) or acetophenone (1b,
1.17mL, 10.0 mmol) in ethanol (EtOH) (10mL). The reaction mixture
was kept at reflux temperature for 1 h and then cooled to 25 °C. The
progress of the reaction was monitored by thin-layer chromatography
(TLC) (ethyl acetate (EtOAc)/hexane= 10:90). The resulting pre-
cipitate was filtered off and washed with a small amount of ice-cold
methanol, then dried under vacuo. The product decomposes at room
temperature or above and should be kept in a refrigerator.
Synthesis of 4-formyl pyrazoles (3) (Vilsmeier-Haack reaction): To an
ice-cold solution of 2a (0.74 g, 5.0mmol) or 2b (1.05 g, 5.0mmol) in
N,N-dimethylformamide (DMF, 20mL), cold phosphoryl chloride
(POCl3, 3 equiv.) was added dropwise, and the mixture was first stirred
at 0 °C for 10min and then was heated to 60 °C and kept at this tem-
perature for 3 h. The progress of the reaction was monitored by TLC
(EtOAc/hexane=20:80). After cooling, the mixture was poured into
ice-cold water (100mL), neutralized with NaOH aqueous solution, and
the precipitate was filtered in vacuo, washed with water and crystallized
from EtOH.
Synthesis of Me-pyrTSC and Ph-pyrTSC: To a solution of 3a
(186mg, 1.0mmol) or 3b (248mg, 1.0mmol) in EtOH (5mL), a cata-
lytic amount of glacial AcOH (0.1mL) and thiosemicarbazide (109mg,
1.2 equiv.) were added, and the reaction mixture was irradiated with
microwave (MW) (80 °C) for 5min (alternatively 2 h under reflux is
sufficient). The completion of the reaction was determined by TLC
(EtOAc/hexane=40:60). The crude product was poured into ice cold
water. The solid thus obtained was filtered in vacuo, washed with ice-
cold water and purified by column chromatography (silica gel, EtOAc/
hexane= 30:70 to EtOAc using gradient elution).
Procedure for the synthesis of Ph-pyrSC: To a solution of 2b
(248mg, 1.0mmol) in EtOH (5mL), semicarbazide hydrochloride
(134mg, 1.2 equiv.) and sodium acetate (NaOAc) (98mg, 1.2 equiv.)
were added, and the reaction mixture was irradiated with MW (80 °C)
for 5min (alternatively 2 h under reflux is sufficient). The completion of
the reaction was determined by TLC (EtOAc/hexane=40:60). The
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Chart 1. Chemical structures of the investigated 2-((3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene)hydrazinecarbothioamide (Me-pyrTSC), 2-((1,3-diphenyl-1H-
pyrazol-4-yl)methylene)hydrazinecarbothioamide (Ph-pyrTSC) and 2-((1,3-diphenyl-1H-pyrazol-4-yl)methylene)hydrazinecarboxamide (Ph-pyrSC) in their neutral
forms (HL).
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crude product was poured into ice-cold water. The solid thus obtained
was filtered in vacuo, washed with ice-cold water and purified by
column chromatography (silica gel, EtOAc).
Reactions under MW-irradiation were carried out with a CEM
Discover SP equipment using dynamic control program with a max-
imum power of 200W. Reactions were monitored by TLC on Kieselgel-
G (Merck Si 254 F) layers (0.25mm thick). Flash chromatography:
Merck silica gel 60, 40–63 μm. Melting points were determined on an
SRS Optimelt digital apparatus.
2.3. Synthesis of Ru(η6-p-cymene) and Cu(II) complexes of Me-pyrTSC and
Ph-pyrTSC
[Ru(η6-p-cymene)(Me-pyrTSC)Cl](Cl) and [Ru(η6-p-cymene)(Ph-
pyrTSC)Cl](Cl) complexes: Me-pyrTSC (0.062mmol) or Ph-pyrTSC
(0.062mmol) and [Ru(η6-p-cymene)(μ-Cl)Cl]2 (0.031mmol) were dis-
solved in 2.0mL ethanol, then 4.5mL water was added. Solvent mixture
was evaporated at room temperature for 5 days. Complexes were re-
crystallized from CH2Cl2, and the complex was obtained as dark red
solid powder (yield: 27% for Me-pyrTSC and 23% for Ph-pyrTSC
complexes, respectively). The isolated complexes were characterized by
ESI-MS, 1H and 13C NMR spectroscopy and UV–vis spectrophotometry;
see experimental data and spectra (Figs. S1–S3) in SI.
[Cu(Me-pyrTSCH−1)2] and [Cu(Ph-pyrTSCH−1)2]: The ligand Me-
pyrTSC (0.084mmol) or Ph-pyrTSC (0.084mmol) was dissolved in
DMSO (3.0mL), then 0.7 mL 0.05M HCl and CuCl2 solution (86.39M in
water, 0.042mmol) was added, and the pH was adjusted to pH ~ 6 by
the addition of 0.1M KOH (0.8mL). Pale brownish precipitate was
formed. The precipitate was decanted, washed with 5–5mL water four
times and dried at 80 °C overnight. Formed complexes (yield: 29% for
Me-pyrTSC and 25% for Ph-pyrTSC) were characterized by ESI-MS, EPR
spectroscopy and UV–vis spectrophotometry, see experimental data and
spectra (Figs. S4–S6) in SI.
2.4. Crystallographic structure determination
Single crystals suitable for X-ray diffraction experiment of ligand Me-
pyrTSC∙H2O (I), complexes [Ru(η6-p-cymene)(Me-pyrTSC)Cl]Cl (II) and
[Cu(Ph-pyrTSCH−1)2] (III) were grown from ethanol:CH2Cl2 (1:1) (I) or
ethanol:water (3:7) (II) or DSMO:CH2Cl2 (2:5) (III) solvent mixtures
containing Ru(η6-p-cymene) and Me-pyrTSC at 1:1 (II), or Cu(II) and Ph-
pyrTSCS at 1:2 (III) metal-to-ligand ratio, respectively. Single crystals
were mounted on loops and transferred to the goniometer. X-ray dif-
fraction data were collected at low temperature (128, 153 and 108 K for
crystals I, II and III respectively) on a Rigaku RAXIS-RAPID II dif-
fractometer using Cu-Kα radiation for crystal I and Mo-Kα radiation for
crystals II and III. Numerical (for crystal I) or empirical (for crystal II and
III) absorption correction [29] were carried out using the program
CrystalClear [30]. Sir2014 [31] and SHELXL [32] under WinGX software
[33] were used for structure solution and refinement, respectively. The
structures were solved by direct methods. The models were refined by
full-matrix least squares on F2. Refinement of non-hydrogen atoms was
carried out with anisotropic temperature factors. Hydrogen atoms were
placed into geometric positions (except for water hydrogens). They were
included in structure factor calculations but they were not refined. The
isotropic displacement parameters of the hydrogen atoms were ap-
proximated from the U(eq) value of the atom they were bonded to. For
crystal I the collection of high angle data was limited because of the use
of copper wavelength. For crystal II disordered structures were detected
therefore some non-hydrogen atoms were also treated with isotropic
displacement parameters. In case of crystal III the platelet crystal shape
prevented the collection of high quality data. The summary of data
collection and refinement parameters are collected in Table S2. Selected
bond lengths and angles of compounds were calculated by PLATON
software [34]. The graphical representation and the edition of CIF files
were done by Mercury [35] and PublCif [36] softwares. The
crystallographic data files for the complexes have been deposited with
the Cambridge Crystallographic Database as CCDC 1942252-1942254.
2.5. Solution studies: pH-potentiometry, UV–visible and 1H NMR
spectroscopy, ESI-MS
The pH-potentiometric titrations for the determination of the exact
concentration of the HCl and KOH solutions, the overall stability con-
stant of [((Ru(η6-p-cymene))2(μ-OH)3]+ species were carried out at
25.0 ± 0.1 °C in DMSO:water 30:70 (v/v) as solvent. Ionic strength of
0.10M (KCl) was used in order to keep the activity coefficients con-
stant. The titrations were performed with carbonate-free KOH solution
of known concentration (0.10M). An Orion 710A pH-meter equipped
with a Metrohm combined electrode (type 6.0234.100) and a Metrohm
665 Dosimat burette were used for the titrations. The electrode system
was calibrated to the pH=−log[H+] scale in the DMSO/water solvent
mixture by means of blank titrations (strong acid vs. strong base: HCl
vs. KOH), similarly to the method suggested by Irving et al. [37] in pure
aqueous solutions. The average water ionization constant pKw was
14.55 ± 0.02, which corresponds well to the literature data
[12–14,38]. The pH-potentiometric titrations were performed in the pH
range 2.0–12.5 using 10 cm3 sample volumes. The concentration of the
[(Ru(η6-p-cymene)(H2O)3]2+ was 2mM. Samples were deoxygenated
by bubbling purified argon through them for approximately 10min
prior to the measurements. Argon was also passed over the solutions
during the titrations. Calculation of the stoichiometry and stability
constants of the complexes was performed with the computer program
HYPERQUAD [39].
An Agilent Cary 8454 diode array spectrophotometer was used to
record the UV–vis spectra in the 200 to 950 nm window. The path
length was varied between 1 and 50mm. Equilibrium constants and the
molar absorbance spectra of the individual species were calculated with
the computer program PSEQUAD [40]. The spectrophotometric titra-
tions were performed on samples containing the ligands with or
without metal ions in the pH range from 2 to 12.5 at 25.0 ± 0.1 °C in
DMSO:water 30:70 (v/v) at an ionic strength of 0.10M (KCl). The
concentration of the ligands was in the range 2–160 μM; the metal-to-
ligand ratios were varied between 1:0.25–1:5.
Distribution coefficient (D7.4) values of ligands were determined by
the traditional shake-flask method in n-octanol/buffered aqueous so-
lution at pH 7.40 (20mM phosphate buffer, 0.10M KCl) at
25.0 ± 0.2 °C as described previously with some modifications [41].
The ligands were dissolved at 50 μM concentrations in n-octanol pre-
saturated with buffer solution. The aqueous solution and n-octanol (1:1
ratio) were gently mixed with 360° vertical rotation (~20 rpm) for 3 h
to avoid emulsion formation, and the mixtures were centrifuged at
5000 rpm for 3min. After separation, UV–vis spectra of the compounds
in the n-octanol phase were compared to those of the original n-octanol
solutions and D7.4 values were calculated as follows: Absorbance (n-
octanol phase after separation) / (Absorbance (original n-octanol solu-
tion)−Absorbance (n-octanol phase after separation)).
1H and 13C NMR spectroscopic studies for the ligands and the Ru(η6-
p-cymene) complexes were carried out on a Bruker Avance III HD
Ascend 500 Plus instrument. Spectra were recorded in CDCl3, in
DMSO‑d6 or in a 30% (v/v) DMSO‑d6/H2O mixture using 0.5–2mM
ligand concentrations varying the metal-to-ligand ratios, the pH
(2−12) or the chloride ion content. In the latter case DMSO‑d6 was
used as reference (δ=2.65 ppm) and WATERGATE method was used
to suppress the solvent resonance.
ESI-MS measurements were performed using a Waters Q-TOF
Premier (Micromass MS Technologies, Manchester, UK) mass spectro-
meter equipped with electrospray ion source. Samples contained
20–50 μM complex dissolved in methanol or 5 μM Ru(η6-p-cymene)
organometallic cation and 5–20 μM ligand in 2% (v/v) ethanol/water
solvent mixture. pH was adjusted by small amount of formic acid, HCl
or KOH.
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2.6. In vitro cell studies
Cell lines and culture conditions: All cell culture reagents were
obtained from Sigma-Aldrich and plastic ware from Sarstedt
(Germany). Human colonic adenocarcinoma cell lines Colo 205 dox-
orubicin-sensitive and Colo 320/MDR-LRP multidrug resistant, ex-
pressing ABCB1 (MDR1)-LRP, ATCC-CCL-220.1 (Colo 320) and CCL-
222 (Colo 205) were purchased from LGC Promochem, Teddington, UK.
MRC-5 human embryonal lung fibroblast cell line (ATCC CCL-171) was
purchased from LGC Promochem, Teddington, UK. In addition, hepa-
tocellular carcinoma cell line (HepG2) and three subtypes of breast
cancer cell lines: the hormone-responsive MCF7, the HER2-positive
SkBr3 and the triple-negative SUM159 cancer cell lines were also used.
The cells were cultured in Roswell Park Memorial Institute (RPMI)
1640 medium for Colo and MRC-5 or in Dulbecco's modified Eagle's
medium (DMEM) for HepG2 and breast cancer cell lines supplemented
with 10% heat-inactivated fetal bovine serum, 2mM L-glutamine, 1mM
sodium pyruvate and 100mM HEPES. The cells were incubated at
37 °C, in a 5% CO2, 95% air atmosphere. All cell lines were detached
with Trypsin-Versene (EDTA) solution for 5min at 37 °C.
MTT and EZ4U assays: Me-pyrTSC, Ph-pyrTSC, Ph-pyrSC and their
copper(II) and Ru(η6-p-cymene) complexes were dissolved in a 90% (v/
v) DMSO/H2O mixture first using 10mM ligand and 0, 5 or 10mM
metal ion concentrations. The metal salts without ligands were also
tested. Cisplatin (Teva) was used as a positive control. Then stock so-
lutions were diluted in complete culture medium, and two-fold serial
dilutions of compounds were prepared in 100 μL of RPMI 1640, hor-
izontally. The semi-adherent colonic adenocarcinoma cells were treated
with Trypsin-Versene (EDTA) solution. They were adjusted to a density
of 1×104 cells in 100 μL of RPMI 1640 medium, and were added to
each well, with the exception of the medium control wells. The final
volume of the wells containing compounds and cells was 200 μL. The
culture plates (Colo205, Colo320, MRC-5) were incubated at 37 °C for
72 h; at the end of the incubation period, 20 μL of MTT solution (from a
stock solution of 5mg/mL) were added to each well. After incubation at
37 °C for 4 h, 100 μL of sodium dodecyl sulfate solution (10% in 0.01M
HCI) were added to each well and the plates were further incubated at
37 °C overnight. The EZ4U assay kit (Biomedica, Wien, Austria) was
used according to manufacturer's instructions in the case of cell lines
HepG2, MCF7, SkBr3 and SUM159. Samples and cells were prepared in
the similar way as in case of the traditional MTT assay. After the 24 h
incubation the compounds were diluted in a volume of 100 μL medium,
then the culture plates were incubated at 37 °C for 24 h; at the end of
the incubation period, 20 μL of MTT solution was added to each well
and incubated for 2 h incubation. The cell growth was determined using
both methods by measuring the optical density (OD) at 450 nm (ref.
620 nm) with a Multiscan EX ELISA reader. Inhibition of the cell growth
(expressed as IC50: inhibitory concentration that reduces by 50% the
growth of the cells exposed to the tested compounds) was determined
from the sigmoid curve where 100− ((ODsample−ODmedium control) /
(ODcell control −ODmedium control))× 100 values were plotted against the
logarithm of compound concentrations. Curves were fitted by GraphPad
Prism software [42] using the sigmoidal dose-response model (com-
paring variable and fixed slopes).
Reactive oxygen species production assay: The ROS measurement
was performed in MCF7 and SUM159 cell lines with 2′,7′-di-
chlorodihydrofluorescein diacetate (DCFH-DA). While penetrating the
cell DCFH-DA is deacetylated by esterases and the forming DCFH inside
the cell reacts with ROS and transforms to the fluorescent 2,7-di-
chlorofluorescein (DCF) in turn. The emission intensity of DCF was
measured at 529 nm using 500 nm excitation wavelength. The SkBr-3
and HepG2 cancer cells were seeded 1× 104 in 100 μL DMEM/10%
fetal bovine serum (FBS) into in 96-well microtiter plates. After al-
lowing cells to adhere for 24 h, 1mM NAC was added to some wells
while 100 μM DCFH-DA was added to all wells. After removing the
media with the excess of DCFH-DA, cells were treated with the
compounds in 1 μM concentration (where the compounds are not toxic
to the cells). The increase in ROS caused by compounds applied was
measured at different time points – prior to treatment and 120min after
the treatment.
Catalase activity and GSH level assays: For both assays cells were
prepared in a same manner. The SUM159 and MCF-7 were seeded in 6-
well plates at density of 5×105 cell/well, and were allowed 24 h to
attach to the well. Then, cells were treated with 1 μM compound and
left for 24 h after which they were harvested, and the dry pellet was
stored at −80 °C until analysis. For analyses, cells were lysed in phos-
phate buffered saline (PBS) by 4 freeze/thaw cycles, and total protein
content was measured by Bradford method [43]. Total GSH was mea-
sured spectrophotometrically at 450 nm (ref. 620 nm) by modified
Tietze method based on reduction of DTNB (Ellman's reagent) to 2-
nitro-5-thiobenzoate (TNB anion) by GSH [44]. Catalase activity was
assayed by measuring H2O2 decomposition by catalase in the whole cell
lysate by Góth method [45].
3. Results and discussion
3.1. Synthesis, solid and solution phase characterization of Me-pyrTSC, Ph-
pyrTSC and Ph-pyrSC
Compounds Me-pyrTSC, Ph-pyrTSC and Ph-pyrSC (Chart 1) were
prepared by the condensation reaction of the corresponding 4-formyl
pyrazoles (pyrazole-4-carbaldehyde) and thiosemicarbazide or semi-
carbazide hydrochloride as described in references [27, 46], although
some modifications were applied, namely microwave-assisted reactions
were performed (Scheme S1). Acid-catalyzed condensation reaction of
acetone (1a) or acetophenone (1b) with phenylhydrazine in refluxing
ethanol led to the corresponding hydrazones (2a and 2b) in excellent
yields. Subsequent cyclization and simultaneous formylation with the
Vilsmeier-Haack reagent (POCl3/DMF) afforded 4-formyl-pyrazoles (3a
and 3b) [46], which were then converted to thiosemicarbazones (Me-
pyrTSC and Ph-pyrTSC) and a semicarbazone (Ph-pyrSC), respectively,
in the presence of acetic acid (Me-pyrTSC and Ph-pyrTSC) or sodium
acetate (Ph-pyrSC) [27] in ethanol under MW irradiation. 1H and 13C
NMR spectra were in agreement with the expected structures of the
intermediates and the final products and the 1H and 13C resonances
published previously [27,46–50] (see Supplementary Information).
The structure of Me-pyrTSC∙H2O (I) was established by single crystal
X-ray diffraction (Fig. 1.a). Me-pyrTSC crystallized in monohydrate
form in triclinic P-1 space group. The molecule has a twisted con-
formation as ring A is twisted from ring B by 27.99(13)° and plane C is
twisted from ring B by 29.5° (Fig. 1.b). An intramolecular hydrogen
bond between N5-H5A…N3 stabilizes the molecular conformation. In
the crystal, dimers are formed between two molecules via the N5-
H5B…S1 hydrogen bonds, and vice versa (Fig. S7). The neighbouring
molecules are further connected through hydrogen bonds with solvent
water molecules. The acidic hydrogen, H2N4 is coordinating to a water
oxygen, and water hydrogens are connected to N2 and S1 atoms. The
packing arrangement is shown in Fig. S7. Selected H-bond distances
and angles are collected in Table S3. Apart from hydrogen bonds a π…π
(off-centered parallel stacking) interaction could be observed between
the two five membered rings for which the distance of 3.8687(14) Å can
be measured.
The molecular structure of Me-pyrTSC∙H2O (I) was compared with
Ph-pyrTSC (PIKRUX) [51] and two other pyrazolyl TSC derivatives
(Ref. codes: CEHHEE and XEBCIS) defined previously [52,53]. CEHHEE
also crystallized with one water molecule, while PIKRUX and XEBCIS
crystallized without solvent inclusion in their crystal lattices. When the
pyrazole rings are overplayed high flexibility of the hydrazine-car-
bothioamide side chain can be seen for the different crystals (Fig. S8).
Since the TSCs and their metal complexes showed much more sig-
nificant cytotoxicity than the semicarbazone Ph-pyrSC (vide infra), our
solution studies were focused on the behaviour of Me-pyrTSC and Ph-
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pyrTSC. The purity of Me-pyrTSC and Ph-pyrTSC was also checked via
1H NMR spectroscopic measurements using maltol as internal standard.
The solid ligand was dissolved in DMSO‑d6 and different amounts of
maltol were added (Fig. S9), then the peak integrals of the ligand were
compared to those of maltol of known concentrations. The compounds
were found to be adequately pure (98.5–100%) and the exact con-
centrations of their stock solutions prepared on a weight-in-volume
basis were calculated taking notice of these values.
The studied compounds have limited water solubility that hindered
the use of pH-potentiometric titrations, therefore the proton dissocia-
tion processes of Me-pyrTSC and Ph-pyrTSC were studied by UV–vis
spectrophotometry at low ligand concentration in 30% (v/v) DMSO/
water solvent mixture, similarly to our former works [12–14,24] to
obtain comparable data. In addition Bz-TSC was involved as a simple
bidentate TSC model for comparison. No spectral changes were ob-
served up to pH 10 (Fig. 2), and the appearance of a well-defined iso-
sbestic point at higher pH values demonstrates that two species (HL,
L−) are involved in the equilibrium. pKa values and the spectra of the
individual ligand species were calculated on the basis of deconvolution
of recorded UV–vis spectra (Table 1). The deprotonation process can be
attributed to the hydrazinic-NH moiety. These TSCs have high and si-
milar pKa values, and we can conclude that they are present in their HL
form at neutral pH. These pKa values are somewhat higher than those of
the α-N-pyridyl TSCs such as Triapine or formaldehyde TSC [24]. 1H
NMR spectra were recorded at various pH values (see the representative
example for Bz-TSC in Fig. S10) and the pH-dependence of the chemical
shifts confirmed the high pKa values of the ligands.
The lipophilic character is an important property of drugs as it
strongly affects the passage via biological membranes. Therefore we
attempted to determine the logD7.4 values for Me-pyrTSC, Ph-pyrTSC
and Bz-TSC using the shake-flask method in n-octanol/buffered aqueous
solution at pH 7.40 (Table 1). The logD7.4 values represent the strong
lipophilic feature of the compounds.
3.2. Solution equilibrium studies, synthesis and structural characterization
of ruthenium(II)(η6-p-cymene) complexes
The complex formation equilibrium processes can be characterized
when the hydrolysis constants of the organoruthenium triaqua cation
are known besides the pKa values of the ligands under the condition
applied. The hydrolytic behaviour of [Ru(η6-p-cymene)(H2O)3]2+ has
been already studied in pure water by Buglyó et al. at 0.2M chloride ion
concentration and in solutions of 0.2M KNO3 [26,54]. In addition the
hydrolysis constants were also determined in 20% (v/v) DMSO/water
solvent mixture by UV–vis spectrophotometric titrations in our former
work using 0.2M KCl ionic strength [55]. Based on the reported con-
stants (Table 2) it could be concluded that the probable coordination of
chloride ions and DMSO suppresses the hydrolysis of this organome-
tallic cation which is then shifted to higher pH values. In the present
work 30% (v/v) DMSO/water solvent mixture and 0.1M KCl ionic
strength was used due to the limited solubility of the ligands in water.
The hydrolysis was followed by pH-potentiometric, UV–vis spectro-
photometric and 1H NMR spectroscopic titrations yielding equilibrium
constants which are in a good agreement with each other (Table 2). It is
important to note that as the chloride ions and DMSO are coordinating
ligands; thus the possible partial displacement of aqua ligand by
chloride or DMSO should be considered and all the determined equi-
librium constants for the organoruthenium species are conditional
constants obtained at the given chloride concentration. 1H NMR spectra
recorded for [Ru(η6-p-cymene)(H2O)3]2+ at various pH values are
shown in Fig. 3, which refer to the presence of only one type of hy-
drolysis product appearing at pH > 5. This species was identified as
the μ-hydroxido bridged dinuclear [(Ru(η6-p-cymene))2(μ-OH)3]+ as it
was suggested in the previous works [26,54].
The complex formation of [Ru(η6-p-cymene)(H2O)3]2+ with the TSC
ligands was found to be fairly slow according to the time-dependent
UV–vis spectra recorded at pH 2.5 and 7.4 (see Fig. S11 in case of Me-
pyrTSC). The chemical equilibrium was reached only within 2 h. In
order to overcome this problem, individual samples were prepared by
the addition of various amounts of KOH, and the actual pH, the UV–vis
and 1H NMR spectra were always measured only after 4 h. Based on the
recorded spectra (Figs. 4 and S12) it could be concluded that the
complex formation proceeds in a great extent already at pH 2. Ac-
cording to the 1H NMR (and UV–vis) spectra no free ligand and orga-
nometallic ion are found at pH~2 with both Me-pyrTSC and Ph-
Fig. 1. (a) Molecular structure of Me-pyrTSC∙H2O (I). Displacement parameters
are drawn at 50% probability level. Hydrogen atoms are omitted for clarity. (b)
Conformation of the compound and assignment of the molecular planes.
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Fig. 2. UV–vis absorption spectra of Ph-pyrTSC (a) and Bz-TSC (b) in the pH range 2–14 in 30% (v/v) DMSO/water solvent mixture in addition to the deprotonation
process. {cPh-pyrTSC=10 μM; cBz-TSC=47 μM; T=25.0 °C; I=0.1M (KCl); l=1 cm}.
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pyrTSC. No complex decomposition was found even at 10 μM con-
centration by UV–vis spectrophotometry. That is the reason why only a
lower limit could be estimated for the formation constants of complexes
those are present at this pH (Table 2). Smaller changes are observed in
the pH range 2.1–4.2 and 10.6–12.1 in the UV–vis spectra (Fig. S12)
with the appearance of isosbestic points representing the equilibrium
processes between two species in both pH ranges.
Two sets of signals of pyrazolyl-CH and the thiosemicarbazone
–CH=protons of the coordinated ligand are seen undoubtedly in the
1H NMR spectra (Fig. 4). The minor species at pH 2.2 (shown with
symbols ● and ▲) becomes predominant with increasing pH and the
chemical shifts of its peaks remain constant; while the upfield shift of
the peaks belonging to the major species (○ and ∆) is observed in the
acidic pH range. On the other hand the peaks of the aromatic CH
protons of the p-cymene moiety show quadruplicated signals (as well as
the signals of the isopropyl-methyl group). The chemically equivalent
protons become magnetically inequivalent most probably as a con-
sequence of the restricted rotation of the arene ring. Based on these
findings we concluded that in the species predominating at pH 2.2 the
ligand is coordinated in its HL form in a mononuclear complex and the
deprotonation of the hydrazinic-NH results in the upfield shift of the
NMR signals. This process could be characterized by a pKa= 3.44 value
(Table 2). The complex characterized by the constant chemical shift is
assumed to be a dinuclear species [(Ru(η6-p-cymene))2(L)2]2+ in which
both ligands coordinate via an (N,S−) donor set while the sulphur
atoms act as μ-bridging ligands. The suggested structures of the various
complexes are presented in Chart 2. X-ray structures of dimeric μ-
thiolato bridged Ru(η6-p-cymene)-TSC complexes in solid phase have
been already reported in the literature [56]. Based on the 1H NMR
spectral data stepwise stability constants for the formation of the di-
meric complexes from the mononuclear species could be computed
(Table 2). Notably, the ratio of the peak integrals of the mononuclear
and dinuclear species was not changed by varying the metal-to-ligand
ratios at pH 2.7 and no other species appeared (besides the unbound
organometallic cation or the free ligand at metal or ligand excess, re-
spectively). However, new peaks were observed at pH > 10.6 and
precipitate was also formed most probably due to the formation of a
neutral mixed hydroxido species [Ru(η6-p-cymene)(L)(OH)] as it was
observed in case of the complexes of other bidentate ligand [57]. A low
intensity doublet peak appeared at 7.2 ppm that is typical to the free p-
cymene representing the release of the arene ligand.
In order to further corroborate the co-existence of the mononuclear
and dinuclear species, a dilution series was prepared in the con-
centration range 11.3–450 μM at pH 7.4 and UV–vis spectra were re-
corded from which molar absorbance spectra were calculated (Fig.
S13). As level of dissociation increases with dilution, formation of
higher fraction of mononuclear species is favoured at lower
Table 1
pKa values determined by UV–vis titrations, λmax, molar absorbance (ε) and logD7.4 values of ligands studied. {T=25 °C; I=0.1M (KCl) in 30% (v/v) DMSO/H2O}.
Medium Me-pyrTSC Ph-pyrTSC Bz-TSC
pKa 30% (v/v) DMSO/H2O 11.53 ± 0.01 11.56 ± 0.01 11.78 ± 0.01
λmax (nm)/ε (M−1 cm−1) 30% (v/v) DMSO/H2O
HL
L−
313/37,690
330/26,825
323/28,420
340/21,979
310/31,450
338/21,290
DMSO 323/39,100 333/30,700 –
logD7.4 n-Octanol/buffer >+1.9 +2.1 ± 0.2 +1.55 ± 0.04
Table 2
Hydrolysis constants of [Ru(η6-p-cymene)(H2O)3]2+ (logβ) and overall (logβ)
and stepwise (logK) stability constants and proton dissociation constants (pKa)
of the Ru(η6-p-cymene) complexes formed with Me-pyrTSC and Ph-pyrTSC.
{T=25 °C; I=0.1M (KCl) in 30% (v/v) DMSO/H2O}.
Method
logβ [(Ru(η6-p-cymene)2(H−1)3]+a pH-metry −14.69 ± 0.05
UV–vis −14.75 ± 0.01
1H NMR −14.64 ± 0.01
Me-pyrTSC Ph-pyrTSC
logβ [Ru(η6-p-cymene)(HL)]2+/+b UV–vis ≥19.0 ≥18.9
pKa [Ru(η6-p-cymene)(HL)]2+/+ 1H NMR 3.50 ± 0.02 3.44 ± 0.02
logβ [Ru(η6-p-cymene)(L)]+/0c cald. ≥15.5 ≥15.5
logK [(Ru(η6-p-cymene))2(L)2]2+d 1H NMR 5.50 ± 0.03 5.34 ± 0.02
logβ [(Ru(η6-p-cymene))2(L)2]2+e cald. ≥36.5 ≥36.3
a [(Ru(η6-p-cymene)2(H−1)3]+= [(Ru(η6-p-cymene))2(OH)3]+. logβ [(Ru
(η6-p-cymene))2(H−1)3]+=−9.36 (pure water, 0.2M KNO3) [54]; =−11.88
(pure water, 0.2M KCl) in addition to logβ [(Ru(η6-p-cym-
ene))2(H−1)2]+=−7.12 [26]; =−15.11 (20% DMSO/H2O, 0.2M KCl) in
addition to logβ [(Ru(η6-p-cymene))2(H−1)2]+=−9.85 [55].
b Estimated values.
c =logβ [Ru(η6-p-cymene)(HL)]2+/+−pKa [Ru(η6-p-cymene)(HL)]2+/+.
d Formation from the mononuclear species.
e =logK [(Ru(η6-p-cymene))2(L)2]2++2× logβ [Ru(η6-p-cymene)(L)]+/0.
δ6.15 5.85 5.55 5.25δ / ppm
pH
11.36
7.20
6.66
6.16
5.69
4.03
3.23
[Ru(η6-cymene)2(OH)3]+
[Ru(η6-cymene)(H2O)3]2+
a) b)
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Fig. 3. (a) Representative 1H NMR
spectra in the low-field region recorded
for [Ru(η6-p-cymene)(H2O)3]2+ in the
pH range 3.2–11.4 in the presence of
0.1M chloride ions in 30% (v/v)
DMSO‑d6/water solvent mixture.
Notably, the aqua ligands in the
triaqua cation are partly replaced by
chloride ions (or DMSO). (b)
Calculated concentration distribution
curves with the hydrolysis constant
determined, symbols (●, □) show the
values calculated on the basis of
1H NMR integrals. {cRu(η6-p-cymene)=
2.5mM; T=25.0 °C; I=0.1M (KCl)}.
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concentration compared to the dimer. It was found that the spectral
characteristics altered significantly upon dilution suggesting the
changed ratio of the mononuclear and dimeric complexes. In addition
ESI-MS spectra were recorded for the [Ru(η6-p-cymene)
(H2O)3]2+−Ph-pyrTSC system at 4 equivalents of ligand excess
(Fig. 5). The major species is the mononuclear complex, and some di-
nuclear and bis-ligand complexes were also found, although formation
of the latter species could not be proved by the 1H NMR measurements
(vide supra).
Based on the equilibrium constants determined it was concluded
that complexes [Ru(η6-p-cymene)(HL)(H2O/Cl)]2+/+, [Ru(η6-p-
cymene)(L)(H2O/Cl)]+/0 (the exact charges of these species are not
known due to the partial coordination of the chloride ion) and [(Ru(η6-
p-cymene))(L)2]2+ are formed at pH 2–4.3, while the latter two species
are present up to pH~9 (see representative concentration distribution
curves in Fig. S14). The predominant species is [(Ru(η6-p-
cymene))2(L)2]2+ at neutral pH. No significant differences in the so-
lution speciation were found between the two studied TSC ligands.
We have attempted to study the solid phase structure of the Ru(η6-p-
cymene) complexes of the TSCs. Solid complexes [Ru(η6-p-cymene)
(TSC)Cl]Cl (where TSC=Me-pyrTSC or Ph-pyrTSC) could be obtained
from 2:1 mixtures of the ligand and the metal precursor prepared in
ethanol:water mixture. Detailed characterization of the synthesized
complexes is found in the SI. 1H and 13C NMR spectra recorded for the
[Ru(η6-p-cymene) complexes undoubtedly reveal that neither the free
metal precursor nor the ligand is present in the solution, peaks assigned
exclusively to the complex are observed. Single crystals of mononuclear
[Ru(η6-p-cymene)(Me-pyrTSC)Cl]Cl (II) complex could be obtained as
well and its crystal structure has been determined by single crystal X-
ray diffraction. Notably, the isolated complexes contain the neutral
Fig. 4. Representative 1H NMR spectra recorded for
[Ru(η6-p-cymene)(H2O)3]2+−Ph-pyrTSC (1:1)
system in the pH range 2.2–11.2 in the presence of
0.1M chloride ions in 30% (v/v) DMSO‑d6/water
solvent mixture. Symbols: pyrazolyl-CH protons ( ,
); thiosemicarbazone –CH=protons ( , ); pyrazolyl
N-phenyl CH protons ( , , , ); p-cymene aromatic
CH protons (a–h); free p-cymene (in the blue frame)
and non-identified peaks (pink rectangle). {cRu(η6-p-
cymene) = 0.5mM; T=25.0 °C; I=0.1M (KCl)}. (For
interpretation of the references to color in this figure
legend, the reader is referred to the web version of
this article.)
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Chart 2. Suggested structures of the Ru(η6-p-cymene) complexes of Me-pyrTSC and Ph-pyrTSC. Exact charges of the mononuclear species are not known due to the
partial coordination of the chloride ion.
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ligands coordinated. II crystallized with one chloride counter ion in
monoclinic P 21/a space group and its ORTEP representation is depicted
in Fig. 6 and the unit cell is shown in Fig. S15. Disordered structures
have been found with disordered positions of the coordinated chlorido
ligand as well as the isopropyl group and the phenyl-pyrazol moiety of
the ligand (Figs. 6, S16–S18).
The two positions are denoted by ‘A’ and ‘B’ and the occupancy ratio
between the two positions was 67% and 33%, respectively. Disordered
atoms of C19, C20, C21 and C6B were refined with isotropic displace-
ment parameters. The Cl2 counter ion is involved in a hydrogen bond
with N2-H2 proton, and thus this part of the molecule is relatively fixed
(Fig. S16). The disordered phenyl rings are turning towards each other
forming columns in the crystal where they can occupy two main posi-
tions. In the case of the ‘A’ position the phenyl rings are arranged
parallel to each other (the angle between the ring planes is 6.5°) and
π…π stacking interaction is formed between the rings (Fig. S17.a). For
the minor position ‘B’, the phenyl ring planes form an angle of 86.4° in
order to evolve a C-H…π connection between the neighbouring rings.
This interaction is further stabilized by a π…π stacking interaction
between phenyl and adjacent pyrazol rings (Fig. S17.b). Hydrogen
bonds towards the chloride counter ion stabilize the packing arrange-
ments in the crystal (Fig. S18.a) in addition to an intramolecular hy-
drogen bond between an isopropyl C20A-H20B and chloride ion Cl1A
(Fig. S18.b). Selected H-bond distances and angles are collected in
Table S4. Notably single crystals of [Ru(η6-p-cymene)(Ph-pyrTSC)Cl]Cl
were also obtained, however the level of disordered structures was even
higher (not shown).
3.3. Solution equilibrium and structural studies of copper(II) complexes
Solution stability of Cu(II) complexes of numerous TSCs has been
already characterized in our previous works [12–14,24]; however these
compounds were tridentate ligands, namely α-N-pyridyl TSCs with
(N,N,S) or salicylaldehyde TSCs with (O,N,S) binding modes, respec-
tively. Despite the fact that Cu(II) complexes of bidentate TSCs are also
widely investigated regarding their anticancer, antibacterial, antiviral
properties and solid structures [2,7], solution speciation data are hardly
available for them in the literature. Herein complex formation equili-
brium processes of Me-pyrTSC and Ph-pyrTSC with Cu(II) were char-
acterized spectrophotometrically in 30% (v/v) DMSO/H2O. Bz-TSC was
also involved for comparison. Representative UV–vis spectra recorded
for Cu(II) – Me-pyrTSC system in the pH range 2.5–10 are shown in
Fig. 7 (and in Fig. S19 for Bz-TSC complexes). Although fairly low li-
gand concentrations were used (10–44 μM), precipitation was observed
at pH > ~6 using both 1:1 and 1:2 metal-to-ligand ratios. Notably in
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Fig. 5. ESI-MS spectra recorded for the [Ru(η6-p-cymene)(H2O)3]2+−Ph-pyrTSC (1:4) system. Peaks identified: [Ru(η6-p-cymene)(L)]+ (a); [Ru(η6-p-cymene)
(L)2H]+ (b); [(Ru(η6-p-cymene))2(L)2–H]+ and [(Ru(η6-p-cymene))2(L)2Cl]+ (c). {cRu(η6-p-cymene)= 5.2 μM; cL=20.8 μM; pH~6; 2% (v/v) ethanol/water}.
Fig. 6. Molecular structure of [Ru(η6-p-cymene)(Me-pyrTSC)Cl]Cl (II).
Displacement parameters are drawn at 50% probability level. Hydrogen atoms
are omitted for clarity.
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Fig. 7. UV–vis absorption spectra of the Cu(II) – Me-pyrTSC (1:2) system in the
pH range 2.52–10.04 in 30% (v/v) DMSO/water solvent mixture. (Dashed line
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shows the molar absorbance spectra of HL, [Cu(L)]+ and [Cu(L)2] species. {cMe-
pyrTSC=10 μM; cCu(II) = 5 μM; T=25.0 °C; I=0.1M (KCl); l=1 cm}.
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the Cu(II) – Bz-TSC (1:2) system the precipitate occurred at somewhat
higher pH (~9). Spectra were also recorded at constant pH (4.6) and
constant ligand (10 μM) or metal ion (10 μM) concentrations varying
the metal-to-ligand ratios (1:5–5:1).
Stability constants for [Cu(L)]+ and [(Cu(L)2] complexes were
computed by the deconvolution of the UV–vis spectra obtained for
samples without precipitation (Table 3, Fig. 7). These data reveal the
considerably higher stability of the pyrazolyl complexes compared to
that of Bz-TSC species. On the other hand all these bidentate TSCs
preferably form bis-ligand complexes, which are neutral species with
rather low water solubility. Significant fraction of bis complexes are
present in the solution even at 1:1 ratio (Fig. 8.a). On the contrary the
salicylaldehyde TSCs form exclusively mono complexes [14]. However,
bis and dinuclear complexes are also formed with α-N-pyridyl TSCs
besides the predominating mono complexes, but only at ligand excess,
and at 1:1 ratio they do not appear in the solution as the concentration
distribution curves show for the Cu(II) – Triapine (1:1) system in
Fig. 8.b.
Most probably as a consequence of the favourable formation of bis-
ligand complexes in solution, [Cu(Me-pyrTSCH−1)2] and [Cu(Ph-
pyrTSCH−1)2] could be isolated from a water:DMSO mixture at higher
concentrations. The characterization of the synthesized complexes was
performed by EPR spectroscopy, ESI-MS and UV–vis spectro-
photometry. The experimental data and spectra collected can be found
in the SI. The data strongly support the suggested structures. It should
be noted that the isotropic EPR spectra show that the bis-ligand copper
(II) - complexes of Ph-pyrTSC and Me-pyrTSC are present in 100% in
DMSO solution. Free copper or mono-complex formation could not be
detected. The low go values reflect high ligand field in the complexes.
The EPR spectra could be described by taking into account two
equivalent nitrogen splittings. Furthermore, single crystals for [Cu(Ph-
pyrTSCH−1)2] (III) could be obtained. The crystal structure has been
determined by X-ray diffraction, and the ORTEP representation is de-
picted in Fig. 9. Complex III crystallized in the triclinic P-1 space group.
The asymmetric centre contains one bis-ligand complex and the half of
another one which is mirrored by an inversion centre in the position of
Cu2. The Cu(II) ions have square planar arrangements, the closest axial
distance of 3.414 Å can be measured between Cu1 and S1 atom of
neighbouring complex. The Cu-Cu closest distances are 4.350 Å for Cu1-
Cu1 and 5.490 Å for Cu1-Cu2. The phenyl rings are turning out of the
pyrazole ring planes with 14.6(5)° for ring (C12-C17) and 37.8(4)° for
ring (C5-C10) and for the other ligand 17.7(4)° for ring (C32-C37) and
30.9(4)° for ring (C25-C30). For the symmetrical complex these values
are 15.6(4) for ring (C52-C57) and 40.0(4) for ring (C45-C50). The
arrangements are stabilized by hydrogen bonds (Table S5) between
N11-H11A…S2 and C6-H6…N25 and by several π…π stacking inter-
actions (three of them are below 4 Å) that arrange the molecules above
each other (Figs. S20, S21). Owing to the steric hindrance with the
possible N or S acceptors, the phenyl protons are not involved in any
hydrogen bonds, except of C6-H6…N25 (Fig. S20).
3.4. In vitro cytotoxicity and antioxidant properties
In order to evaluate the anticancer properties of Me-pyrTSC, Ph-
pyrTSC, Ph-pyrSC and their Ru(II)(η6-p-cymene) and Cu(II) complexes,
as a first step a cytotoxicity colorimetric MTT assay was applied in
doxorubicin-sensitive (Colo205) and multidrug resistant (Colo320)
human colonic adenocarcinoma cell lines. The resistance of Colo320
cells is primarily mediated by the overexpression of ABCB1 (P-glyco-
protein), a member of the ATP-binding cassette (ABC) transporter fa-
mily, which pumps out xenobiotics from the cells. In addition, cyto-
toxicity was measured in normal human embryonal lung fibroblast cells
(MRC5). The determined IC50 values are collected in Table 4. The
corresponding metal ions as CuCl2 and the precursor [Ru(η6-cymene)Cl
(μ-Cl)]2 were also tested for comparison. The complexes of the ligands
were prepared in a 90% (v/v) DMSO/water mixture in situ by mixing
the ligand with one or half equimolar concentration of the organome-
tallic cation or Cu(II). In case of the Ru(II)(η6-p-cymene) complexes
always 1:1 metal-to-ligand ratio was used, while Cu(II) complexes were
tested at 0.5:1 ratio as well to ensure the formation of bis complexes. In
the final samples the DMSO content was always lower than 1%. Cis-
platin was used as a positive control.
The Ru(η6-p-cymene) precursor did not show cytotoxic effect, while
CuCl2 was moderately toxic in the tested cell lines. The ligands were not
cytotoxic against the normal fibroblast cells, while IC50 values in the
range 33–76 μM were obtained in both human adenocarcinoma cell
lines. In the presence of both Ru(η6-p-cymene) and Cu(II) lower IC50
values were determined compared to the respective ligands as a con-
sequence of the complex formation; however, the Cu(II) complexes
were much more cytotoxic in the case of the thiosemicarbazones. The
complex formation with the metal ions always resulted in greater ac-
tivity than cisplatin. The Cu(II) and Ru(η6-p-cymene) complexes
showed selectivity against the cancer cells compared to the normal cells
in all cases, moreover complexes of Me-pyrTSC at 1:1 metal-to-ligand
ratio revealed a measurable selectivity against the multidrug resistant
cancer cell line (Colo320) over the Colo205 cells.
Since the studied TSCs were highly synergistic with CuCl2, and the
Table 3
Overall stability constants (logβ) of the Cu(II) complexes formed with the stu-
died ligands for comparison determined by UV–vis titrations. {T=25 °C;
I=0.1M (KCl); 30% (v/v) DMSO/H2O}.
Me-pyrTSC Ph-pyrTSC Bz-TSC
logβ [Cu(L)]+ 12.22 ± 0.03 12.57 ± 0.08 10.94 ± 0.06
logβ [(Cu(L)2] 24.89 ± 0.09 25.53 ± 0.09 21.49 ± 0.09
Fig. 8. Concentration distribution curves calculated for the Cu(II) – Me-pyrTSC system based on the stability constants determined (a) (dashed lines show the pH
range where precipitation occurs); and for Cu(II) – Triapine system based on data taken from Ref. [12] (b). {cL= cCu=10 μM; T=25.0 °C; I=0.1M (KCl); 30% (v/
v) DMSO/H2O}.
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higher cytotoxic activity of certain TSCs is associated with induction of
reactive oxygen species [17,18], Me-pyrTSC, Ph-pyrTSC and their Cu
(II) complexes were further investigated regarding their intracellular
ROS production, catalase activity and their effect on cellular GSH level.
These assays were performed in various breast cancer cells for the li-
gands and for the complexes as well. Cytotoxicity was also measured in
the hormone-responsive MCF7, the HER2-positive SkBr3 and the triple-
negative SUM159 breast cancer cell lines, in addition to the hepato-
cellular carcinoma cell line (HepG2), and the in vitro cytotoxicity data
are shown in Table 5. Similarly to the Colo205 and Colo320 cell lines,
the ligands exhibited undoubtedly synergistic effect with the Cu(II)
ions. The Cu(II) salt and the ligands were less toxic against these cell
lines compared to Colo205/320. The complexation resulted in higher
cytotoxicity in the SkBr3 and SUM159 cells.
In order to investigate the basis of cytotoxicity, ROS production was
measured in MCF7 and SUM159 cell lines using the ROS sensitive cell
permeable dye DCFDA (Fig. S22, Table S6). Results are expressed as
fold change in the emission intensities after exposure to the test com-
pound relative to the solvent control (without the use of NAC). The
ligands and their Cu(II) complexes showed no ability to produce ROS
under the applied conditions (1 μM ligand concentration where the
compounds are non-cytotoxic, 120min incubation time); moreover all
showed weak antioxidant activity as somewhat lower intensities were
measured compared to those of the solvent blank. Addition of the re-
ducing agent NAC decreased the ROS production in the control samples
and almost in all cases of the compounds tested (except Me-pyrTSC with
and without Cu(II) in SUM159 cell); however, the decrease of the in-
tensity was more significant in case of the MCF7 cells.
Catalase is an antioxidant enzyme converting H2O2 to water and
oxygen, thus it is able to protect cells against H2O2 stress. Catalase
activity was measured in MCF7 and SUM159 cell lines in order to
characterize the antioxidant status of the cells and results are shown in
Fig. 10.a. Different effect was observed for the two kinds of cell lines,
namely the ligands and the Cu(II) complexes revealed similar and low
catalase activity in MCF7 cells, while increased catalase activity was
seen in SUM159 cells. However, comparing the behaviour of the com-
pounds to solvent control, a decreased activity was detected in the
latter cells. Notably, the compounds were more cytotoxic in SUM159
than in MCF7 cells (see IC50 values in Table 5), thus the increased
catalase activity did not protect the SUM159 cells against the toxicity of
the tested compounds. Disturbances in GSH homeostasis are often
Fig. 9. Molecular structure of [Cu(Ph-pyrTSCH−1)2] (III). Displacement parameters are drawn at 50% probability level. Hydrogen atoms are omitted for clarity.
Table 4
In vitro cytotoxicity (IC50 values in μM) of Me-pyrTSC, Ph-pyrTSC, Ph-pyrSC and
their Ru(II)(η6-p-cymene) and Cu(II) complexes in Colo205, Colo320 and MRC-
5 cell lines. {72 h exposure}.
IC50 (μM) Colo205 Colo320 MRC-5
Cu(II)a 23.9 ± 5.1 15.5 ± 0.8 16.0 ± 6.6
Ru(η6-p-cymene)b > 100 >100 >100
Me-pyrTSC 49.6 ± 2.5 75.6 ± 13.5 > 100
Ph-pyrTSC 50.0 ± 5.7 32.9 ± 2.6 > 100
Ph-pyrSC 69.8 ± 6.9 74.4 ± 11.8 > 100
Cu(II)-Me-pyrTSC (1:1) 6.27 ± 1.53 2.99 ± 0.77 6.79 ± 2.64
Cu(II)-Me-pyrTSC (0.5:1) 5.88 ± 1.14 5.17 ± 1.06 10.2 ± 3.9
Cu(II)-Ph-pyrTSC (0.5:1) 5.05 ± 0.94 4.16 ± 0.64 11.9 ± 2.0
Cu(II)-Ph-pyrSC (0.5:1) 43.1 ± 5.8 28.8 ± 1.9 73.7 ± 10.6
Ru(η6-p-cymene)-Me-pyrTSC (1:1) 23.8 ± 5.8 12.40 ± 5.4 32.0 ± 7.1
Ru(η6-p-cymene)-Ph-pyrTSC (1:1) 11.9 ± 3.4 11.2 ± 4.8 24.7 ± 2.2
Ru(η6-p-cymene)-Ph-pyrSC (1:1) 42.2 ± 9.2 48.5 ± 10.0 56.6 ± 8.4
Cisplatin 60.4 ± 9.5 25.4 ± 2.5 55.7 ± 10.6
a Stock solution prepared by dissolution of CuCl2.
b Stock solution prepared by dissolution of [Ru(η6-p-cymene)(μ-Cl)Cl]2.
Table 5
In vitro cytotoxicity (IC50 values in μM) of Me-pyrTSC, Ph-pyrTSC and their Cu
(II) complexes in MCF7, SkBr3, SUM159 and HepG2 cell lines. {24 h exposure}.
MCF7 SkBr3 SUM159 HepG2
Cu(II)a > 100 >50 73.69 ± 0.52 >50
Me-pyrTSC >100 >50 >100 >50
Ph-pyrTSC >100 24.5 ± 2.2 40.6 ± 1.5 >50
Cu(II)-Me-pyrTSC
(0.5:1)
19.1 ± 2.0 5.85 ± 0.53 6.54 ± 0.13 12.0 ± 1.8
Cu(II)-Ph-pyrTSC
(0.5:1)
18.9 ± 2.0 4.01 ± 0.26 4.22 ± 0.27 21.68 ± 0.20
a Stock solution prepared by dissolution of CuCl2.
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involved in progression of cancer [58]. The decrease in the GSH level
can lead to an increased susceptibility to oxidative stress, while the
elevated GSH concentration increases the antioxidant capacity and can
consequently increase the resistance to oxidative stress. Based on the
data obtained for the GSH levels (Fig. 10.b) the monitored two un-
treated cell lines exhibited similar values. Addition of both the solvent
DMSO mixture and CuCl2 resulted in increased GSH content in SUM159
cells, and they did not affect the GSH level in MCF7. The tested com-
pounds (Me-pyrTSC, Ph-pyrTSC and their Cu(II) complexes) had dif-
ferent effects, since the GSH level was decreased in SUM159 cells, while
increased GSH concentration was measured in the MCF7 cells compared
to the controls. No significant changes were seen upon addition of Cu
(II) to the ligands.
These results suggest that the tested compounds may cause changes
in antioxidant transcription factor Nrf2, which is responsible for tran-
scription of enzymes needed for GSH synthesis [59] independently of
ROS production. Certainly, as these two cell lines represent breast
cancer of different malignancy with different metabolic capacities, it
would be interesting to investigate in the near future how these dif-
ferences occur in the light of therapy resistance.
4. Conclusions
Solution speciation, solid phase structure and anticancer properties
of two bidentate pyrazolyl thiosemicarbazones Me-pyrTSC, Ph-pyrTSC
and their Cu(II) and Ru(η6-p-cymene) complexes were investigated. The
characterization of the proton dissociation processes by UV–vis spec-
trophotometry in partially aqueous solution revealed that the ligands
are present in their neutral form in a wide pH range (up to pH~10), as
the deprotonation of the hydrazinic NH moiety takes place only in the
basic pH range (pKa: 11.53 (Me-pyrTSC), 11.78 (Ph-pyrTSC)). This
feature also contributes to the strongly lipophilic character of the li-
gands. The stoichiometry and stability of the Cu(II) and Ru(η6-p-
cymene) complexes were studied in 30% (v/v) DMSO/H2O solvent
mixture with a focus on the most plausible species that emerged at
physiological pH. For the solution speciation studies mainly UV–vis
spectrophotometry was used and 1H NMR spectroscopy and ESI-MS
were also applied for the Ru(η6-p-cymene) complexes. The complex
formation with Cu(II) was found to be fast, while longer waiting time
(> 1.5 h) was necessary to reach the complete equilibrium in case of
the Ru(η6-p-cymene) species.
Based on the solution equilibrium studies we concluded that
mononuclear [Ru(η6-p-cymene)(HL)(Z)]2+/+ and [Ru(η6-p-cymene)(L)
(Z)]+/0 species are formed at pH < 4 (where Z=H2O/DMSO or Cl−),
while a dinuclear [(Ru(η6-p-cymene))2(L)2]2+ complex becomes pre-
dominating at higher pH values including the physiological pH. These
complexes possess significantly high solution stability. In [Ru(η6-p-
cymene)(HL)]2+/+ the ligand coordinates in its neutral form via (N,S)
donor set and [Ru(η6-p-cymene)(L)]+/0 is formed by the deprotonation
of the hydrazinic nitrogen (pKa: 3.50, 3.44 for Me-pyrTSC, Ph-pyrTSC,
respectively). The (N,S−) coordination mode in the latter species was
confirmed by X-ray crystallography. Most probably the ligands also
coordinate via the (N,S−) donor set in the dinuclear [(Ru(η6-p-
cymene))2(L)2]2+ complex, although the sulphur atoms act as μ-brid-
ging ligands between the two metal centres. Cu(II) forms mono [CuL]+
and bis [CuL2] complexes with the studied pyrazolyl thiosemicarba-
zones and their reference compound Bz-TSC. Formation of [CuL2] is
favourable at neutral pH and these complexes are characterized by poor
water solubility. X-ray diffraction study of [Cu(Ph-pyrTSCH−1)2]
showed the bidentate coordination of the ligands via (N,S−) donor set
with deprotonated hydrazinic nitrogens. The observed trend for the
stability of the Cu(II) complexes is the following: Ph-pyrTSC > Me-
pyrTSC≫ Bz-TSC, thus the presence of the pyrazolyl moiety un-
doubtedly increased the solution stability.
In vitro cytotoxicity of Me-pyrTSC, Ph-pyrTSC and the semi-
carbazone Ph-pyrSC, as well as of their Cu(II) and Ru(η6-p-cymene)
complexes was measured in a cell line pair, namely in Colo205 (human
colonic adenocarcinoma) and its multidrug resistant counterpart
Colo320. Toxicity of the compounds was also monitored in a human
embryonal lung fibroblast cell line (MRC-5). The tested ligands showed
moderate cytotoxicity against the cancerous cells, but were not toxic
against MRC-5. Complexation with the metal ions has increased the
cytotoxic activity in all cases, and a stronger synergism was observed in
case of the thiosemicarbazones. The most active Cu(II) complexes and
their ligands were further investigated. Cytotoxicity of Me-pyrTSC, Ph-
pyrTSC in the absence and in the presence of Cu(II) ions was screened in
three breast cancer cell lines (MCF7, SkBr3, SUM159) and in a hepa-
tocellular carcinoma cell line (HepG2). The Cu(II) complexes were
found to be again more active than their ligands. No ROS production
was detected in MCF7 and SUM159 cells at 1 μM concentration of the
compounds and they did not affect significantly the catalase activity in
MCF7 cells. The SUM159 cells have relatively high catalase activity, but
it was diminished upon addition of the tested compounds. The com-
pounds resulted in a decreased GSH level in SUM159 cells, while higher
GSH concentration was seen in the MCF7 cells comparing to the con-
trols. It suggests that the studied compounds interfere with the GSH
synthesis without ROS production. However, the Cu(II) complexation
did not bring differences in the GSH levels.
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Abbreviations
Bz-TSC benzaldehyde thiosemicarbazone
D7.4 distribution coefficient
DCF 2,7-dichlorofluorescein
DCFH-DA 2,7-dichlorodihydrofluorescein diacetate
DMEM Dulbecco's modified Eagle's medium
DMF N,N-dimethylformamide
DMSO dimethyl sulfoxide
DSS 4,4-dimethyl-4-silapentane-1-sulfonic acid
DTNB 2,2′-dinitro-5,5′-dithiodibenzoic acid, Ellman's reagent
ESI-MS electrospray ionization mass spectrometry
EtOAc ethyl acetate
EtOH ethanol
FBS fetal bovine serum
GSH L-glutathione
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
Me-pyrTSC 2-((3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene)hy-
drazinecarbothioamide
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide
MW microwave
NAC N-acetyl-cysteine
OD optical density
PBS phosphate buffer saline
Ph-pyrSC 2-((1,3-diphenyl-1H-pyrazol-4-yl)methylene)hy-
drazinecarboxamide
Ph-pyrTSC 2-((1,3-diphenyl-1H-pyrazol-4-yl)methylene)hy-
drazinecarbothioamide
ROS reactive oxygen species
RPMI Roswell Park Memorial Institute
TLC thin-layer chromatography
Triapine 3-aminopyridine-2-carboxaldehyde thiosemicarbazone
TSC thiosemicarbazone
UV–vis UV–visible
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